ATO CHLOE 525 Cream

Components (in 1g)

• Betamethasonedipropionate: 0.4mg
• Clotrimazole: 3mg Diphenhydramine: 2mg, Salicylic Acid: 2mg

How to store

• Store in an airtight container at 15° to 25°

Effective against

• Allergic dermatitis, contact dermatitis, atopic dermatitis, seborrheic dermatitis, eczema, intertrigo, exfoliative dermatitis, lichen simplex chronicus.

Dosage

• Apply a thin layer to and around the affected area in the morning once a day and rub lightly.

Precautions for Use

• 1. This drug must not be used by any of the following patients or on the following areas.
  • 1) Wounds or mucous membranes
  • 2) Patients with bacterial (skin tuberculosis, syphilis, etc.), fungal (candidiasis, ringworm, etc.), viral (herpes zoster, herpes simplex, chickenpox, hydrocephalus, etc.), animal (scabies, pubic lice, etc.) skin infection
  • 3) Patients with hypersensitivity to or a history of hypersensitivity to this drug or its components
  • 4) Patients with eczematous otitis externa with perforation of the tympanic membrane (There may be a delay in healing at the perforated site.)
  • 5) Patients with ulcers (except Behcet's disease), second-degree burns and frostbite
  • 6) Patients with perioral dermatitis, common acne, or rosacea
  • 7) Patients with hypersensitivity to or a history of hypersensitivity to bacitracin or aminoglucoside antibiotics such as streptomycin, kanamycin, gentamicin, and neomycin
  • 8) Patients with hypersensitivity to or a history of hypersensitivity to imidazole antibiotics (cross-reactivity)
• 2. Caution must be taken when applying to the following patients.
  • 1) Pregnant women or women who may be pregnant and lactating women
  • 2) Infants and children
  • 3) Because this drug contains propylene glycol, it should be administered with caution to patients who are hypersensitive to this ingredient or have a history of allergy.
• 3. Side Effects
  • 1) Skin
    ① Infection: Bacterial (infectious impetigo, folliculitis, etc.) or viral infection of the skin may appear. [It is more common when the occlusive dressing technique (ODT) has been used]. If such symptoms appear, use an appropriate antibacterial or antifungal agent in combination, and if the symptoms do not improve quickly, discontinue use.
    ② Common skin symptoms: If symptoms such as folliculitis, swelling, skin irritation, stinging, fever, burning sensation, rash, redness, itching, dry skin, pustular dermatitis, allergic contact dermatitis, heat rash, aggravation of wounds, pressure sores, and pustules appear, discontinue use and consult your doctor or pharmacist.
    ③ Long-term use: Steroid acne, steroid skin (skin atrophy, capillary dilatation, purpura), steroid rosacea, perioral dermatitis (erythema, papule, capillary dilatation, scabbing, scale all over the face and around the mouth), ichthyosis skin change, hair growth, loss of pigmentation, etc. may occur. If these symptoms appear, slowly reduce the dosage and change to a drug that does not contain corticosteroids. In the case of a local infection, the incidence of secondary infection may increase due to the weakening of the defense system.
  • Endocrine system: Extensive use in large quantities or over a long period of time may result in inhibition of pituitary/interrenal system due to systemic administration of corticosteroids as a result of using the occlusive dressing technique.
  • 3) Eyes: When used on the skin of the eyelids, take caution as it may cause an increase in intraocular pressure and glaucoma. Posterior subcapsular cataract, glaucoma, etc. may appear when using in large quantities or using over a long period of time, especially when using the occlusive dressing technique. Unexplained blurred vision may also occur.
• 4. General Precautions
  • 1) Follow the prescribed usage and dosage.
  • 2) When used on a child, it must be used under the guidance and supervision of a guardian.
  • 3) Discontinue use if symptoms do not improve or if symptoms worsen.
  • 4) If symptoms improve, discontinue use as soon as possible.
  • 5) Except in special cases, avoid long-term use, use in large quantities, and use of the occlusive dressing technique. Pay particular attention to this caution when using on newborns and children.
  • 6) Since local side effects such as skin atrophy and steroid flushing may occur, the severity of symptoms should be fully considered, especially when used on the face, neck, genitals, and dermis of the intertriginous area.
  • 7) Sensitization may occur, so observe closely and discontinue use if symptoms of sensitization (itchiness, redness, edema, papules, blisters, etc.) appear.
  • 8) Do not use for a long period of time. Even if you do not use the drug continuously, it is not recommended to use it for more than 2 to 3 weeks where possible. When using strong corticosteroids on the face or genital area, special attention is required. Avoid using the product for more than 1 week.
• 5. Application to Pregnant and Lactating Women
  • 1) In animal studies, teratogenicity has been observed with topical application of this drug.
  • 2) This drug has not been proven safe for use by pregnant women, so it should not be used in pregnant women or women who may be pregnant.
• 6. Application to Children
  • 1) Caution should be taken when applying to children as the ratio of body surface area to body weight is greater than that of adults, so hypothalamic-pituitary-adrenal axis inhibition, Cushing's syndrome, and developmental disorders are more likely to occur due to corticosteroids.
  • 2) Care must be taken as diapers may exhibit the same effects as using the occlusive dressing technique.
• 7. Precautions for Application
  • 1) Do not use on the eyes. If the product gets into your eyes, rinse immediately with water. If symptoms are severe, seek medical attention from an ophthalmologist.
  • 2) Do not use for purposes other than treatment, such as makeup or after shaving.
  • 3) Do not use the occlusive dressing technique without the supervision of a doctor.
• 8. Storage Precautions
  • Keep out of reach of children.
• 9. Other Matters
  • There has been a report that psoriatic erythroderma and pustular psoriasis appear during treatment or after discontinuation of treatment in case of long-term use or use in large quantities in psoriasis patients.